Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 8,241 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Humans Clear all
Active, not recruiting Phase 3 Interventional Results available

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

NCT05113251
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
Interventions
Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, cyclophosphamide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
927 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
22
States / cities
Springdale, Arkansas • Beverly Hills, California • Glendale, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 22, 2026, 8:25 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Positron Emission Tomography (PET) Imaging Studies With NIS Reporter

NCT02907073
View directory record Official record
Conditions
Myeloma, Endometrial Cancer
Interventions
BF4
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Oct 22, 2026, 8:25 PM EDT
Completed Phase 2 Interventional Results available

Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer

NCT01084083
View directory record Official record
Conditions
Head and Neck Cancer, Precancerous Condition
Interventions
cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel, Cisplatin
Biological · Radiation · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
121
States / cities
Birmingham, Alabama • Greenbrae, California • Palo Alto, California + 86 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 22, 2026, 8:25 PM EDT
Recruiting Not applicable Interventional

Decoding and Selective Modulation of Human Memory During Awake/Sleep Cycles

NCT05452122
View directory record Official record
Conditions
Memory, Delayed
Interventions
Auditory and Electrical Stimulation
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 22, 2026, 8:25 PM EDT
Completed No phase listed Observational

Quality Improvement Project - Evaluation of Current Standard of Care for Feeding Practices in the NICU

NCT01204983
View directory record Official record
Conditions
Infant, Very Low Birth Weight
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Day and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 22, 2026, 8:25 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers Results available

Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants

NCT02568566
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma
Interventions
Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
9 Years to 11 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
2
States / cities
Tucson, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 22, 2026, 8:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Implant Pharmacokinetic and Pharmacodynamic Study

NCT03634137
View directory record Official record
Conditions
Healthy
Interventions
Afamelanotide Group 1, Afamelanotide Group 2
Drug
Lead sponsor
Clinuvel Pharmaceuticals Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 22, 2026, 8:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of the Pharmacokinetics of Oral Selenium Compounds in Humans Before and Following Supplementation

NCT00342966
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
20 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2010
U.S. locations
2
States / cities
Beltsville, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 8:25 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

NCT01667731
View directory record Official record
Conditions
Hepatitis C, Human Immunodeficiency Virus
Interventions
SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 22, 2026, 8:25 PM EDT
Active, not recruiting Phase 1 Interventional

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

NCT05489237
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
Interventions
IDRX-42
Drug
Lead sponsor
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 8:25 PM EDT
Active, not recruiting Not applicable Interventional

Studying the Effects of Brain Stimulation on Cognitive Control and Associated EEG in Human Subjects.

NCT05251454
View directory record Official record
Conditions
Cognitive Deficit
Interventions
Brain Stimulation
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 22, 2026, 8:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD

NCT02406651
View directory record Official record
Conditions
Acute Graft vs Host Disease
Interventions
Recombinant Human Interleukin-22 IgG2-Fc (F-652), Systemic Corticosteroids
Drug
Lead sponsor
EVIVE Biotechnology
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Duarte, California • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 22, 2026, 8:25 PM EDT
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection

NCT01590654
View directory record Official record
Conditions
Hepatitis B
Interventions
Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts GS-9620
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Indianapolis, Indiana • New Orleans, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 22, 2026, 8:25 PM EDT
Completed Phase 2 Interventional Results available

Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

NCT00987337
View directory record Official record
Conditions
Hepatitis, Hepatitis C
Interventions
Filibuvir, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
30
States / cities
Anaheim, California • Coronado, California • La Jolla, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 22, 2026, 8:25 PM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

NCT07807956
View directory record Official record
Conditions
Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Cancer
Interventions
ABBV-253
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Grand Rapids, Michigan • Huntersville, North Carolina • Irving, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 8:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Low-Cost Molecular Cervical Cancer Screening Study

NCT01231945
View directory record Official record
Conditions
DNA Probes, E6 Protein, Uterine Cervical Neoplasms, HPV
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years to 65 Years · Female only
Enrollment
7,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 8:25 PM EDT
Completed Phase 1Phase 2 Interventional

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

NCT00911963
View directory record Official record
Conditions
Hepatitis C
Interventions
VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 22, 2026, 8:25 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Safety and Efficacy of Recombinant Human Prolactin

NCT00438490
View directory record Official record
Conditions
Healthy
Interventions
Recombinant Human Prolactin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Oct 22, 2026, 8:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of NSAIDs on Bone Metabolism Following Exercise

NCT05512013
View directory record Official record
Conditions
Bone Resorption, Stress Fracture, Bone Injury
Interventions
Ibuprofen 800 mg, Celecoxib 200mg, Flurbiprofen 100 mg, Placebo
Drug
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 42 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 22, 2026, 8:25 PM EDT
Recruiting Phase 1 Interventional

A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

NCT02852213
View directory record Official record
Conditions
AADC Deficiency
Interventions
AAV2-hAADC
Drug
Lead sponsor
Krzysztof Bankiewicz
Other
Eligibility
24 Months and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2037
U.S. locations
3
States / cities
San Francisco, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 22, 2026, 8:25 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

NCT01728324
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment, Ribavirin-placebo: 8-week treatment, Faldaprevir-placebo: 8-week treatment, Faldaprevir: 16-week treatment, Ribavirin: 16-week treatment, RBV: 24-week treatment, BI 207127: 16-week treatment
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
31
States / cities
North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 22, 2026, 8:25 PM EDT
Recruiting Not applicable Interventional

Using a mHealth App to Improve Quality-of-Life Outcomes in Black Prostate Cancer Survivors

NCT06651359
View directory record Official record
Conditions
Prostate Cancer
Interventions
Surveys for Quality of Life, Surveys and mHealth App access
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Male only
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Tallahassee, Florida • Milledgeville, Georgia • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 22, 2026, 8:25 PM EDT
Terminated Phase 1 Interventional

CAM Procedure With BMAC for Shoulder OA

NCT04826224
View directory record Official record
Conditions
Shoulder Osteoarthritis
Interventions
Concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.
Biological
Lead sponsor
Shane A. Shapiro
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 22, 2026, 8:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly

NCT00772889
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine GSK2186877A, GSK Biologicals' Fluarix™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years and older
Enrollment
971 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
9
States / cities
Clearwater, Florida • Coral Gables, Florida • Milford, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 22, 2026, 8:25 PM EDT